The Technical Analyst
Castle Biosciences Inc [CSTL]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Castle Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
3.33% $20.16
America/New_York / 26 apr 2024 @ 11:03
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 553.39 mill |
| EPS: | -2.14 |
| P/E: | -9.42 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 27.45 mill |
| Avg Daily Volume: | 0.230 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.42 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.50x |
| Company: PE -9.42 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 19.11 - 21.31 ( +/- 5.43%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-23 | Maetzold Derek J | Sell | 215 | Common Stock |
| 2024-04-23 | Maetzold Derek J | Sell | 215 | Common Stock |
| 2024-04-23 | Maetzold Derek J | Sell | 421 | Common Stock |
| 2024-04-23 | Maetzold Derek J | Sell | 68 | Common Stock |
| 2024-04-23 | Maetzold Derek J | Sell | 69 | Common Stock |
| INSIDER POWER |
|---|
| 34.49 |
| Last 99 transactions |
| Buy: 329 657 | Sell: 164 281 |
Forecast:
12:42 - $19.81
Live Trading Signals (every 1 min)
Forecast
1: 11:12 - $20.14
Forecast 2: 12:02 - $20.00
Forecast 3: 12:42 - $19.81
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $20.16 (3.33% ) |
| Volume | 0.0148 mill |
| Avg. Vol. | 0.230 mill |
| % of Avg. Vol | 6.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CSTL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:32 | buy | $23.67 | N/A | Active |
|---|
CSTL
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Last 10 Buy Signals
Latest Press Releases
2024-04-11 07:00:00 - Press Release
Castle Biosciences To Release First Quarter 2024 Financial Results And Host Conference Call On Thursday, May 2, 2024
Friendswood, texas--(business wire)---- $cstl #castlebiosciences--castle will release its financial results for the first quarter ended march 31, 2024, after the close of market on thursday, may 2, 2024.
2024-04-10 17:00:00 - Press Release
Castle Biosciences Celebrates Esophageal Cancer Awareness Month Through Advocacy And Educational Collaborations
Friendswood, texas--(business wire)---- $cstl #castlebiosciences--castle recognizes the importance of esophageal cancer awareness month and is providing its support of key programs and initiatives throughout april.
2024-04-10 07:00:00 - Press Release
Castle Biosciences' Chief Financial Officer Frank Stokes Recognized As A Top Cfo Of Houston For Second Consecutive Year
Friendswood, texas--(business wire)---- $cstl #castlebiosciences--for the second year in a row, castle's chief financial officer, frank stokes, has been selected as a top 25 cfo of houston by top cfos.
2024-04-04 16:30:00 - Press Release
Presentations At Eado Highlight Potential Impact Of Castle Biosciences' Decisiondx®-melanoma And Decisiondx®-scc Tests On The Management Of Patients With Skin Cancer
Friendswood, texas--(business wire)---- $cstl #cstl--castle will share new data on its decisiondx-melanoma and decisiondx-scc tests at the 20th european association of dermato-oncology (eado) congress.
2024-04-02 07:00:00 - Press Release
Castle Biosciences To Present At The 23rd Annual Needham Virtual Healthcare Conference
Friendswood, texas--(business wire)---- $cstl #castlebiosciences--castle's executive management will present a company overview at the 23rd annual needham virtual healthcare conference tuesday, 4/9/24 at 12:45pm et.
Latest News
2024-03-12 07:00:00 - Business Wire
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management will present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum.
2024-03-08 16:30:00 - Business Wire
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AAD2024--Castle Biosciences announces it will share data across its dermatologic portfolio of gene expression profile tests at the 2024 AAD Annual Meeting.
2024-02-28 21:30:22 - Seeking Alpha
Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript
2024-02-28 19:31:10 - Zacks Investment Research
Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Castle Biosciences, Inc. (CSTL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
2024-02-28 18:41:04 - Zacks Investment Research
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.78 per share a year ago.
2023-11-08 13:00:00 - Business Wire
Castle Biosciences to Present at Upcoming Investor Conferences
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management will present a company overview at three investor conferences later this month.
2023-11-02 21:02:31 - Zacks Investment Research
Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q3 Earnings
Although the revenue and EPS for Castle Biosciences, Inc. (CSTL) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2023-09-05 07:00:00 - Business Wire
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences today announced that Derek Maetzold and Frank Stokes will present a company overview at Baird's 2023 Global Healthcare Conference.
2023-08-03 11:17:10 - The Motley Fool
Why Castle Biosciences Stock Is Jumping Today
Castle reported stronger Q2 revenue growth and a lower net loss than analysts anticipated. The company also raised its full-year revenue outlook.
2023-08-02 20:58:29 - Zacks Investment Research
Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q2 Earnings
While the top- and bottom-line numbers for Castle Biosciences, Inc. (CSTL) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.